Tourmaline Bio, Inc. (TRML) Stock Ticker
TRML right now
Market factors today
Unlock the full TRML picture
About Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
TRML stock facts
| Ticker symbol | TRML |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.2B |
| CEO | Sandeep C. Kulkarni |
| Employees | 74 |
| Headquarters | New York City, NY, US |
| IPO date | 2021-05-07 |
| Website | www.tourmalinebio.com |
What you can see for TRML on Tickr
Live TRML price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TRML report.
Rankings
FAQ
What is the ticker symbol for Tourmaline Bio, Inc.?
The ticker symbol for Tourmaline Bio, Inc. is TRML, listed on the NASDAQ Global Select.
What is TRML?
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.